At 10am on the first Thursday of every month, OTM organises presentations at which some of its investee companies pitch to investors. If you would like an invite to the next event on Thursday 3rd February 2022, please enter your details here.
These companies from the OT(S)EIS portfolio is seeking additional EIS investment. They presented virtually on Thursday 6th January at 10 am. Anyone who wishes to contact the founders or Oxford Technology team with additional questions should contact us. Oxford Technology plans to host these investor presentations on the first Thursday of every month, free to subscribers to OT(S)EIS, and initially free to everyone.
To invest in this opportunity, you need to be a 'sophisticated investor' or a 'high net worth individual'. The definitions of these terms can be found here. You can receive the documents to invest by filling out this form.
OT(S)EIS made an SEIS investment in Lupe in February 2017 at 68p/share (effectively 34p including income tax relief). The ex-Dyson engineer founders had an idea for a better vacuum cleaner, one which would both clean better and which would also be better for the planet, designed to last for a long time, with parts that could be replaced if necessary, rather than having a three year life before being thrown into landfill.
In this aim they have succeeded. The first production units arrived in 2020 and there have been hundreds of reviews to date, virtually all of them positive although none as nerdy, objective (detailed measurement of actual suction achieved) and super enthusiastic as Vacuum Wars, who did tests on 45 of the leading brands of cordless vacuum cleaners. When they presented the results, they covered up the name of the winner (Lupe!) to start with because it was so far ahead of all the others. And then they explain why Lupe is so much better, even when being operated on low power than others being operated at full power.
Forbes went on to describe Lupe as The Rolls Royce of Vacuums.
Lupe is now struggling with the problems of success. Even through advertising and marketing spend was cut in the months before Christmas, Lupe sold out of stock entirely, with the majority of sales being to the US. Despite this, in just one month more than 250 people paid up front to receive their Lupes in March, and the pre-orders continue to be strong.
Lupe was not able to place an order in advance because it didn’t have the money available to place the order until it had sold the existing stock. So Lupe is now seeking to raise up to £500k of working capital at £4.50 per share, a modest increase on the £3.50 of the last fundraising. The shares will qualify for EIS tax relief.
The principal aim of this modest round is to allow for another 6 months of trading performance to be delivered, avoid going out of stock again, and support a much higher valuation in the second half of 2022.
OT(S)EIS made an SEIS investment in Animal Dynamics in 2015 at 14p/share (effectively 7p/share including income tax relief). The investment came out of the Animal Flight research group of the Zoology department of Oxford University, and the plan was to use this knowledge to make better flying machines and also more efficient systems for propelling ships.
Animal Dynamics has been a great success and has won contracts from both the US and UK military for various autonomous flying machines. These initial contracts are for research and demonstration systems.
Now the company is focused on scaling up for the full scale production of STM, an autonomous cargo drone system. This machine (like a powered paraglider) will fly autonomously with a 135Kg payload and a range of 400km. The potential uses are legion, and include delivering food and water to hurricane or earthquake victims when roads have been destroyed and supplying front line troops.
The company is raising £10m at 97p per share, the same share price as the previous fundraising. Of this £5m will be provided by Oxford Sciences Enterprises (OSE), AD’s largest shareholder.
After the presentations and before the Q&A session, Anita D’Attellis gave a live performance of Variations 2, 4 & 5 of Bach’s Goldberg Variations.
Finally, there was be a Q&A session, during which the presenters answered questions that have been submitted by the audience during the pitch.
If you have any questions about Oxford Technology or any of the companies presenting, please contact us.
Two companies from the OTSEIS portfolio presented virtually on 2nd December 2021
OT(S)EIS has made the following investments in Nikalyte Ltd.
06/08/2019 £50,000 £0.95 SEIS
24/02/2020 £16,000 £0.95 SEIS
16/10/2020 £78,000 £0.95 EIS
The purpose of the investment was to enable Nikalyte to develop an instrument which would enable researchers to lay down metal nanoparticles of many types on more or less any type of substrate and in a very short time - about 30 minutes. The hope was that this instrument, which would also be inexpensive (£60,000) would become a standard in many or most of the departments of universities and companies which study nanoparticles, which is to say in the majority of universities worldwide, and also in many materials and pharma companies.
Since the investment, Nikalyte has made good progress.
Nikalyte has made the first easy-to-use starting system, known as the NL50, which is the instrument which it hopes will become a standard piece of equipment in teaching and research labs. By changing a small number of operating conditions it is possible for the operator to change the mean size of the nanoparticles’ size distribution. Operators can also switch quickly and easily between materials to generate nanoparticles from a wide range of materials. The NL50 is both easy to use and flexible, making it ideal for shared use. In addition Nikalyte has developed an advanced nanoparticle research instrument, the NL-UHV, which offers enhanced control over nanoparticle properties and additional capability to filter and measure the nanoparticle size. The NL-UHV also includes an option to generate complex alloy nanoparticles from up to 3 different materials.
However, Covid could not have come at a worse time for Nikalyte. All round the world, university labs and often company research labs were shut for the best part of 18 months. The result was that sales were not achieved at the rate originally hoped which, in turn, means that Nikalyte needs to raise additional capital.
But there are good reasons for believing that Nikalyte will ultimately be successful. OT(S)EIS will invest, but we can only invest £45,000. So we would like others to join in to raise a total of £200,000. The share price will be as before, £0.95, which is a pre money valuation of £615k, much lower than is the case for any other of our investees. If Nikalyte does anything like as well as it hopes, this valuation would multiply many fold. At the moment, Nikalyte’s overheads are £10,000 per month, with the 3 key founders working 3 days per week, to save costs. So £200k would buy a good runway of time, even without any sales. But there are good reasons for thinking that sales will come. The sale of one NL50 every three months would be breakeven.
1. Since universities opened up in the summer a number of Institutes have expressed a desire to have an NL50 available to their researchers and several are now applying for grants and or putting the purchase of an NL50 into their budgets for next year. These include York University, Johnson Matthey and 4 Institutes in China including Beihand University in Beijing, and the National Center for Nanoscience and Technology . Further to these NL50 prospects a number of Universities have already or intend to submit grant proposals for the NL-UHV. These include Oxford University, Warwick University Manufacturing group and Manchester Metropolitan University. One NL-UHV sale has already been made to Leoben University in Germany.
2. In the last few months, it has become apparent that the NL50 is able to produce substrates for SERS (Surface Enhanced Raman Spectroscopy) which perform better than anything else (or so it appears) have shown superior performance to most commercially available SERS substrates and in many cases at much lower cost. SERS is used by forensic departments world-wide to detect traces of substances such as drugs, or explosives. Or to detect contaminants in water or for medical diagnoses. So Nikalyte has begun to receive orders for gold nanoparticle SERS substrates at £5 - £7 each, and has so far received orders ranging from £390 to £1,500 from Merck, Ben-Gurion University and Agilent Technologies. The global market for SERS is expected approach $200m by 2025, according to one market research company. According to another, to $861m by 2026. In any event, it is a large and potentially profitable market for Nikalyte.
The sale of SERs substrates should be a very good complimentary business to selling instruments. Nikalyte is in the process of setting up an online payment order and system on its website so that customers can order as easily as possible and pay in advance by card. To support Nikalyte’s entry into the SERS market and the grow the SERS business further the company has partnered with Wasatch Photonics, who is a leading supplier of spectroscopy equipment worldwide and Agilent Technologies, who supply forensics and diagnostic equipment. These relationships provide access to current customers and the opportunity for joint development of products for new SERS markets.
OT(S)EIS made an SEIS investment of £90,800 in OVO Biomanufacturing in November at £10.99 per share. £50,000 had already been raised, and the company had also received a small grant. This should be enough to enable OVO to get started and achieve its first sales, but they would like to raise up to another £100,000 at the same share price to give a longer runway.
OVO is a spin-out from Warwick and Coventry Universities. It has a technology which it believes could halve the cost of manufacturing vaccines. Each year about 1 bn eggs are used to grow flu vaccine and the overall cost works out at about £1 per egg. The eggs have to be super sterile and the hens housed in sterile conditions etc. OVO believes that its technology could halve this cost, saving £500m per year. OVIO is now in contact with several of the major vaccine manufacturing companies.
OVO has achieved a significant technical breakthrough in the weeks immediately following our agreement to invest which makes it think that its technology is even more useful.
When the first vaccine is prepared only a very small quantity will exist. The task of the manufacturer is to produce this vaccine in huge quantities, enough to vaccinate hundreds of millions of people. (Or billions in the case of Covid)
To do this, manufacturers culture the vaccine in eggs. The vaccine enters the cells in the eggs and there takes over the reproduction mechanism, so that each infected cell then produces 1000’s of copies of the vaccine. Within 48 hours the egg may contain 10bn copies of the vaccine. But viruses are crude and create lots of imperfect copies. (It is this quality of viruses that enable them to mutate and create variants.) As well as particles with minor deficiencies, the vaccines also produce much smaller particles maybe with only 20% of the mass of the original vaccine. But if these smaller particles, known as DIPs (Defective Interfering Particles) also have the correct starting and ending codons, they will also take over the replication mechanism of the cell and replicate. But because they are much shorter, they will replicate faster and will quickly come to vastly outnumber the vaccine.
There are two strands to OVOs technology.
1. Software which is able to estimate what will happen to the rate of future vaccine production given the mix of Vaccine and the various DIPs at an early stage of the production process. The aim here is to maximise the output of vaccine.
2. To deliberately create a vaccine which produces DIPs which which will then prevent the real virus from being able to reproduce since it will instead have its reproduction mechanism taken over to produce almost only DIPs.
One company from the OTSEIS portfolio presented virtually on 4th November 2021
When OT(S)EIS first invested in Expend in 2014, the company consisted of two people with an idea about how the handling of business expenses and spending, a major problem for many companies, might be made better. Then, the basic idea was that all information should be collected at source using a payment card linked to the Expend system and mobile app, allowing an employee to take a photo of the receipt as soon as it is received and have all the information sent neatly to their finance department and accounting system. Since then, Expend has grown and evolved into a cutting edge innovative mobile app and web platform that takes expense management for SMEs to the next level.
Today, Expend provides businesses with optional contactless payment cards, receipt & invoice management that works with their existing payment methods, mileage tracking, spending approvals and expense reimbursements all in one platform.
Expend saves businesses time, money and effort by consolidating management, payment and accounting tools into a highly streamlined process. Company finance directors using Expend know about every expense as it occurs and can control and adjust company spending to meet changing needs.
Expend is used by a growing number of companies ranging from 1 - 500 employees paying a monthly fee per user. Their business model also sees them receive a small percentage interchange fee on all transactions whenever an Expend card is used. They have ever increasing interest from large commercial firms looking to partner and utilise their technology in order to add value to their own customer bases. Expend has been growing rapidly with almost every month being a new high. In Sep 2019 the monthly revenue was ca £11,000. In Sept 2021, two years later, revenue was more than £42,000.
Expend is now seeking to raise up to £1,000,000 at 15p per share. The funds will be used to continue to add additional team resources to help facilitate the commercial opportunities they have and to accelerate growth.
Expend regularly receives approaches from US fintech companies seeking to grow by acquisition, and this is the most likely exit route for investors. They have also been approached by some well known financial firms looking to partner with them and offer Expend's technology to their business customers, this is a sales channel that Expend anticipates will grow quickly.
The presentation was given by Johnny Vowles, CEO of Expend.
Two companies from the OTSEIS portfolio presented virtually on 7th October 2021
Curileum has been making very good progress, and is now seeking to raise £1.5m at £3 per share to be able to further exemplify the performance of its two leading compounds/treatments and to be able to negotiate with pharma companies from a position of relative financial strength. Dr Jeff Moore, the founder and CEO will make the presentation.
1. ULI -15 (Formerly known as PLE-015) but now renamed – ULI means powerful in Chinese.
Curileum received the first results of a trial of ULI-15 during September. Although the sample size was small, the results were dramatic. The treated mice showed a 10-fold reduction in polyps (the first stage of bowel cancer) compared to the untreated controls. So ULI, which should be safe since it is a component of a Chinese medicine that has been taken for centuries, is potentially a pill that would be taken by millions each day, to slow or maybe prevent the development of bowel cancer.
2 ATZ Stem Cell Therapy
Curileum has developed a treatment for anal fistulas, a painful and at the moment incurable condition that affects 40% of patients with Crohn’s disease. In a pig model, Curileum’s stem cell therapy has shown complete healing, including the growth of new blood vessels, compared to controls which showed no healing.
These dramatic results are partly the result of the fact that Curileum is based at St Mark’s hospital, the only hospital in the world which does nothing else apart from diseases of the gut, of which there are many. Curileum receives samples of both diseased and healthy human gut tissue and is able to grow organoids from these to try to understand what is happening at the cellular level.
Lightpoint is seeking to raise working capital, either by selling EIS qualifying shares at 99p per share, with a discount to 79p for early shareholders, or by means of a convertible loan note. The former would suit individual investors who can benefit from the 30% tax refund and tax-free gains that come with an EIS investment. The latter might suit institutional investors or those who cannot benefit from EIS tax relief. This compares to 65p per share in March 2019, since when Lightpoint’s product, SENSEI®, has been approved for sale in the US, Europe, UK and Australia; achieved its first sales; and signed significant agreements with strategic partners.
SENSEI® is used in keyhole and robotic cancer surgery, enabling surgeons to see which tissue is cancerous and which is not while they are operating. The patient is injected with a cancer-targeted imaging agent that concentrates in cancerous cells, meaning that they can be located by the SENSEI® probe which detects the emissions from the agent. A video on the website (www.lightpointmedical.com) shows this in action.
Unsurprisingly surgeons the world over find this enormously helpful. Dr David Tuch, the founder of Lightpoint, was once in the operating theatre with a surgeon doing prostate cancer surgery. The camera revealed a growth on the nerve bundle. At the time the SENSEI® probe was not in use. The surgeon said (paraphrased): Now I have to play God. If that growth is benign, I can leave it. But if it is cancerous, I should cut it out. But if I cut it out, the consequences for the patient are severe including no more sex, and incontinence. Your technology can tell me what I should do.
At the moment, the SENSEI® probe is sold as a single-use device and is priced at £700. However, the plan is to make it a re-useable device to ensure a very high margin for the device.
In March, Lightpoint appointed a new CEO, Graeme Smith, with over three decades of experience in commercialising medical devices, to focus on the commercialisation of SENSEI®. Commercial agreements for the distribution of SENSEI® have already been signed in multiple territories with more in the pipeline. The company has also signed a co-marketing agreement with a global surgical robotics company.
In August 2021, Lightpoint signed a Strategic Collaboration Agreement with Telix Pharmaceuticals Ltd, by which Telix’s cancer-targeted imaging agents will be used with SENSEI®. In the words of the press release: The collaboration between our two companies has the potential to transform the outcomes for patients across a range of cancer types.
The presentation was given by Graeme Smith, CEO of Lightpoint Medical.
Finally, there was be a Q&A session, during which the presenters will answer questions that have been submitted by the audience during the pitch.
One company from the OTSEIS portfolio presented virtually on 2nd September 2021
In vitro fertilisation (IVF) is a large and growing market both for humans and animals. One of the key steps in the process is the selection of healthy sperm cells, characterised by swimming fast and straight. Cytoswim has developed an easy-to-use chip, essentially an obstacle course for sperm. The sperm are all placed at the starting gates and the sperm which complete the course first are then selected. No centrifugation is involved. Other methods involve centrifugation which is possibly damaging to the cells.
There are currently 5m human IVF cycles in the world each year, and rising, with 70k in the UK, 900k in Europe, and 300k in the US. Cytoswim will sell its product ‘spermalign’ for £125. So potential sales of c£600m. In addition there are about 500k IVF cycles in cattle, but carried out in relatively few central sites, mainly in the US and South America, so this market should be relatively easy to address.
Spermalign has now been used in animals and has produced excellent results. The cleavage rate increased from 63% to 72% and the 8-day blastocyst viability (the first stage of pregnancy) from 34% to 41%.
Cytoswim is now seeking to raise up to £500,000 at £6.18 per share, a pre money valuation of £2m . The investment will qualify for EIS tax relief. OT(S)EIS will be investing £70,000 (and possibly a little more) towards this total.
It is hoped that this fundraising will take the company through to breakeven. The funds will be used to achieve the following:
Patent costs £50k
Regulatory (CE mark etc) £140k
Clinical studies/sales & Marketing £130k
Overheads and contingency £140k
The last of these expenditures is forecast to be at the end of 2023. Initial sales are expected to be achieved in 2021 with sales rising steadily during 2022, but only for use in animals.
When its product, ‘spermalign,’ receives regulatory approval for use in humans, Cytoswim’s aim is to sell 50,000 at £125 each (sales £6.25m) by 2026. Based on the prices at which companies in the IVF field have been acquired, the hope is that this would value Cytoswim at about £36m.
After the presentation and before questions, Anita D'Attellis gave a live performance of Schubert Impromptu, op. 142, no. 3
Finally, there was be a Q&A session, during which the presenters answered questions which have been submitted by the audience during the pitch.
One company from the OTSEIS portfolio presented virtually on 1st July 2021
Covatic, in which OT(S)EIS made an initial SEIS investment in 2017 is beginning to make excellent progress. It has now signed its first deals with some of the largest broadcasters in the world, including Bauer Media, Comcast, and Liberty Global. These deals are for an initial three years and are worth, £90k per year, £600k per year, and a minimum of £400k per year respectively over the initial three year periods.
However, the first payments under these contracts come in April (£90,000), August (£600,000) and November (£400k). So Covatic is seeking to raise up to £600k to provide working capital, and began a fundraising in March at a share price £9.41, which compares to £16 per share in 2018.
Since Covatic started this round in March, it has raised over £300k, so there is about £300k still available. During this time, the team have launched their new product ‘A-Type’. This has had a very positive market reaction and they have pipeline of 91 active opportunities, with a discounted value of £4m Annual Run Rate (ARR) by December.
In addition to the contracts mentioned above, since the start of the round, Covatic has been selected to build Sky News and Sky Sports future adtech privacy approach. The contract is an ad revenue sharing deal with a minimum commitment. The expectation is circa £40k per month on a three year deal.
Covatic is looking to achieve a monthly revenue of around £100k per month by the end of Q3 with this growing to over £250k by the end of December.
In addition to these contracts with large organisations, Covatic is offering the use of its software for a monthly fee to some 200 smaller organisations. This is forecast to begin generating about £20,000 per month from September, rising to £40,000 by December.
At the moment Google and many others collect as much data about people as they can, (by means of cookies) and are then able to know their browsing history, what they buy, where they are and where they travel. And this data is then used to target advertising to users. That same data is also sold to others.
There is growing concern that this huge invasion of privacy is not acceptable. But at the same time it is accepted that revenue from advertising is the means by which many industries, inc sport and television are funded. And if there must be advertising, then it is probably better for both the sender and receiver that it is targeted. It is better that someone who likes fishing receives an ad about a better fishing rod, than someone who doesn’t.
This is the problem which Covatic is seeking to solve. If you have the Sky app on your phone (with Covatic’s tech), this will gather data about you and your viewing habits and what you like and where you are at what time. But your browsing history will not be tracked. And crucially, all this data will remain on your phone (this is in complete contrast to Google, and the industry as a whole who store this information on their own servers and use the data themselves to target ads). Then the Covatic enabled app will be able to target ads (so fishing rods for fishermen) and also content (so clips of Manchester United goals to Manchester United fans) but the personal details of the recipient will never leave the user’s device. The app will suggest a fishing ad, but the sender of the ad will not know the details of the recipent or anything about him/her.
So Covatic’s hope is that Google’s mode of operation will become increasingly unacceptable both to users and to regulators and that Covatic will become the standard privacy-compliant means of targeting advertising in future. The fact that Covatic has now signed deals with major broadcasters, including Comcast (the largest media organisation in the world which also owns Sky) is a very good indication that Covatic is on the right track.
After the presentation and before questions, Anita D'Attellis gave a live performance of Schubert Impromptu, op. 142, no. 2 in Ab major.
Finally, there was a Q&A session, during which the presenters answered questions which were submitted by the audience during the pitch.
Two companies from the OTM portfolio presented virtually on 3rd June 2021
OxVent arose out of Covid, and was initially established in great haste to design and manufacture low cost ventilators for the UK. There was an initial order for 3,000 ventilators from the UK govt, and the govt agreed to pay for the parts. The initial partnership was between Smith and Nephew, Kings College and Oxford University. In the event, the govt did not require these ventilators and Smith and Nephew decided to pull out, because their core business was in wound-care rather than ventilators.
So OxVent was formed and starts 3,000 ventilators which may be sold for £1,500 each, so £4.5m in total. It is estimated that it will take about 3 hours labour to assemble each one.
OxVent is now located in a small factory unit on an industrial estate near Oxford which is currently full to the brim with all the components.
However, the ventilator still needs regulatory approval before it can be sold. Approval to sell the ventilator in the US under the FDA ‘emergency use’ protocol has been applied for and it is hoped that this approval might be granted in June or July, although this is not certain. If this happens, then it is believed that most countries would either substantially shorten their own processes or accept FDA as sufficient certification, allowing it to be sold.
In many counties, especially in Africa, it is thought that local assembly would be preferred, so the sale would be of the components at maybe £650 to £750 rather than a fully assembled ventilator.
But the future is another ventilator. As a result of getting into ventilator design, academics in the engineering department at Oxford University have produced an altogether better and cheaper design of ventilator, which has no moving parts at all. Furthermore it is controlled by pressure, so that the patient could wear a mask and could themselves control the rate of breathing. A patent will be applied for, and further details cannot be given here. But if all goes well, it is believed that this design could become widely used globally in future.
OxVent seeks to raise up to £250,000 at 0.2p per share, which values the company at £1.2m pre money. Investors will receive a mixture of SEIS and EIS shares, with the ratio determined by the amount of money raised by 30 June, when the investment round will be closed. £70,000 of SEIS shares remain.
OxVent sees the most significant growth in the ventilator market coming from low to middle income countries where the annual market size is currently close to US$1 billion and growing yearly at 7%. To that end, OxVent has agreements in place with JRG healthcare in India and is working with groups in East Africa and Latin America to build its commercial base.
Acquisition, either by an in-territory partner, or by a multinational seeking a product range tailored for those markets is thought to be the most likely exit opportunity.
Atelerix is having a rights issue, seeking to raise £450,000 at 80p per share. This compares to 82p per share of the initial SEIS investment in 2018 and subsequent EIS raises at £1.70 per share in 2019 and £1.95 in 2020.
Atelerix has developed a range of alginate gels derived from seaweed which enable cells to be shipped and stored at temperatures above freezing for periods of up to 2 weeks. Quite how long depends on the cell type. This enables cells that could otherwise not be transported to go from their source to the labs that need them.
Essentially the Atelerix technology works exactly as hoped and is useful. Atelerix spent a great deal of time and effort on one global company which it was hoped would place very large orders and so to launch Atelerix commercially. But is transpired that the company would have had to make other changes to its operating procedures to do this and in the end , decided not to proceed. Then Covid resulted in most labs in the world being closed.
Atelerix had employed staff and increased overheads in the expectation of sales. So now Atelerix has run out of money. So it has now reduced overheads and is seeking to raise £450,000 at a reduced share price, which, it is hoped, will take the company to cash flow breakeven. More than £100,000 of this has already been raised from existing shareholders including the founder who is acting as unpaid interim CEO.
Atelerix is now focusing on leukobags. This is currently a £100m market but growing fast. Leukobags contain 500ml of white blood cells and are regularly shipped from the US to labs in Europe ands Asia. Blood donors may be paid in the US, but not elsewhere in the world, with the result that the US is the only country with an abundant supply of blood. The cells begin to deteriorate as soon as they leave the body. Some of the cells types are completely destroyed by freezing so that this is not an option. Atelerix has shown that the cells will survive for up to 14 days in their gel. Atelerix is now in discussion with the three largest suppliers of leukobags in the US, all of whom are interested.
One company from the OTM portfolio presented virtually on 6th May 2021
Agricultural seeds are very expensive - some more than £100,000/kg. It is important that the highest possible yield is achieved. One of the steps in preparing them for sale is to sterilise the seeds, so no bacteria or fungi can damage their growth prospects. Most agricultural seeds were treated with chemicals, but due to their damaging nature most of these have been banned. Zayndu has developed a method of sterilising seeds using a plasma generated in a chamber which does no damage at all to the environment or the seeds. It is also a faster and easier process with no drying or washing steps required. Furthermore, the treatment actually results in a higher % of the seeds germinating. In one case the % of seeds which germinated increased from 78% to 85%. Or, put another way, the % of seeds which did not germinate fell from 22% to 15%. This is of huge potential commercial value to farmers.
The founders of Zayndu are Dr Ralph Weir and Dr Felipe Iza. The technology was developed at Loughborough University, which is also a shareholder in the business. Zayndu has interest from several large seed companies. The business model will be a pay per use or monthly rental model.
OT(S)EIS invested £133,505 just before the end of the 2021 tax year. This investment was an EIS rather than an SEIS investment because Zayndu had already been in receipt of funding from Innovate UK. This investment secured the release of a £700,000 Innovate UK loan. To retain this loan, the founders needed to raise an additional £120,000 of EIS investment. This money was raised within an hour of the end of the presentation, and Zayndu are no longer accepting further investment at the current time.
If you have any questions about Oxford Technology or any of the companies presenting, please contact us.